Search Results
288 items found for "Cell cycle"
- 📰 GPCR Weekly News, February 6 to 12, 2023
Listing Rule 5635(c)(4) arcoscreen is one of the 13 biotech companies to discover in western in 2023 Call
- Adhesion GPCR Consortium Newsletter - May 2024
The family of adhesion GPCRs called the Latrophilins or ADGRLs first captured my attention due to their
- 📰 GPCR Weekly News, March 18 to 24, 2024
receptors in colitis GPCRs in Oncology and Immunology Polarizing itch Biochemical pharmacology of adenylyl cyclases
- PH-Binding Motif in PAR4 Oncogene: From Molecular Mechanism to Drug Design
Pc(4-4), a lead backbone cyclic peptide, was selected out of a mini-library, directed toward PAR2&4 PH-binding
- Synthesis and characterization of an orally bioavailable small molecule agonist of the apelin recept
Previously, we had identified a novel pyrazole-based agonist 1 ((S)-N-(1-(cyclobutylamino)-1-oxo-5-(piperidin -1-yl)pentan-3-yl)-1-cyclopentyl-5-(2,6-dimethoxyphenyl)-1H-pyrazole-3-carboxamide hydrochloride) of
- Structure of Mycobacterium tuberculosis Cya, an evolutionary ancestor of the mammalian membrane...
Structure of Mycobacterium tuberculosis Cya, an evolutionary ancestor of the mammalian membrane adenylyl cyclases " Mycobacterium tuberculosis adenylyl cyclase (AC) Rv1625c/Cya is an evolutionary ancestor of the mammalian Although the vital role of ACs in cellular signalling is well established, the function of their transmembrane
- ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated ...
TAVNEOS® (avacopan) has been approved within the European Union in combination with a rituximab or cyclophosphamide TAVNEOS will receive marketing authorization in all member states of the European Union, as well as in
- Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European ...
orally administered selective complement 5a receptor inhibitor, in combination with a rituximab or cyclophosphamide